Morgan Stanley Applied Molecular Transport Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.16 - $0.34 $1,149 - $2,442	-7,184 Reduced 55.22%	5,825 $0
Q2 2023 Aug 14, 2023	SELL	$0.24 - $0.37 $102,204 - $157,564	-425,850 Reduced 97.04%	13,009 $3,000
Q1 2023 May 15, 2023	BUY	$0.32 - $0.68 $136,766 - $290,628	427,395 Added 3728.15%	438,859 $140,000
Q4 2022 Feb 14, 2023	SELL	$0.35 - $1.26 $139,058 - $500,611	-397,311 Reduced 97.2%	11,464 $4,000
Q3 2022 Nov 14, 2022	SELL	$1.12 - $3.12 $720,773 - $2.01 Million	-643,548 Reduced 61.15%	408,775 $398,000
Q2 2022 Oct 27, 2022	BUY	$2.76 - $7.65 $110,852 - $307,254	40,164 Added 3.97%	1,052,323 $3.06 Million
Q2 2022 Aug 15, 2022	BUY	$2.76 - $7.65 $110,852 - $307,254	40,164 Added 3.97%	1,052,323 $3.06 Million
Q1 2022 Oct 27, 2022	SELL	$5.63 - $13.88 $226,123 - $557,476	-40,164 Reduced 3.82%	1,012,159 $7.61 Million
Q1 2022 May 13, 2022	BUY	$5.63 - $13.88 $2.63 Million - $6.49 Million	467,263 Added 85.75%	1,012,159 $7.61 Million
Q4 2021 Feb 14, 2022	BUY	$13.23 - $26.05 $4.4 Million - $8.66 Million	332,412 Added 156.44%	544,896 $7.62 Million
Q3 2021 Nov 15, 2021	BUY	$25.87 - $46.61 $5.5 Million - $9.9 Million	212,484 New	212,484 $5.5 Million

9.42K

Ticker AMTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,900,600
Description
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of r...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.